CN Patent

CN120441497A — 前列腺特异性膜抗原（psma）配体及其用途

Assigned to Advanced Accelerator Applications Italy SRL · Expires 2025-08-08 · 1y expired

What this patent protects

本披露内容涉及前列腺特异性膜抗原(PSMA)配体。特别地，本披露内容涉及具有谷氨酸‑脲‑赖氨酸(GUL)部分和可包含放射性金属的螯合剂的PSMA配体。本披露内容还涉及这些化合物在成像和前列腺癌治疗中的用途。

USPTO Abstract

本披露内容涉及前列腺特异性膜抗原(PSMA)配体。特别地，本披露内容涉及具有谷氨酸‑脲‑赖氨酸(GUL)部分和可包含放射性金属的螯合剂的PSMA配体。本披露内容还涉及这些化合物在成像和前列腺癌治疗中的用途。

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: CN120441497A
Jurisdiction: CN
Classification: —
Expires: 2025-08-08
Drug substance claim: No
Drug product claim: No
Assignee: Advanced Accelerator Applications Italy SRL
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.